Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.229 SEK | +13.37% | +7.51% | -97.71% |
05-16 | Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024 | |
05-16 | Xbrane Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-97.71% | 28.85M | |
+42.42% | 50.93B | |
-0.42% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.87% | 26.02B | |
-21.69% | 18.9B | |
+7.52% | 13.21B | |
+24.20% | 12.17B | |
+29.99% | 12.16B |
- Stock Market
- Equities
- XBRANE Stock
- News Xbrane Biopharma AB
- Xbrane Biopharma, Stada Sign US Licensing Deal for Lucentis Biosimilar